Editas Medicine Announces First Quarter 2018 Results and Update – Virginian-Pilot
|
Editas Medicine Announces First Quarter 2018 Results and Update
Virginian-Pilot About Editas Medicine As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious … |
